CD33 and acute myeloid leukemia: Recently, this technology has also been applied to manipulate DCs, and it has been shown that DCs transduced with a CAR directed against CD33 (highly expressed on acute myeloid leukemia (AML) cells) are able to enhance anti-AML CAR T cell cytotoxicity in vitro [166].